Erwan Salaun1, Haïfa Mahjoub2, Abdellaziz Dahou2, Patrick Mathieu2, Éric Larose2, Jean-Pierre Després2, Josep Rodés-Cabau2, Benoit J Arsenault2, Rishi Puri3, Marie-Annick Clavel2, Philippe Pibarot4. 1. Institut Universitaire de Cardiologie et de Pneumologie de Québec/Québec Heart & Lung Institute, Laval University, Quebec City, Québec, Canada; Centre de Résonance Magnétique Biologique et Médicale (CRMBM), UMR 7339, Centre National de la Recherche Scientifique, Aix-Marseille Université, Marseille, France. 2. Institut Universitaire de Cardiologie et de Pneumologie de Québec/Québec Heart & Lung Institute, Laval University, Quebec City, Québec, Canada. 3. Cleveland Clinic Coordinating Center for Clinical Research (C5R), Cleveland, Ohio. 4. Institut Universitaire de Cardiologie et de Pneumologie de Québec/Québec Heart & Lung Institute, Laval University, Quebec City, Québec, Canada. Electronic address: Philippe.Pibarot@med.ulaval.ca.
Abstract
BACKGROUND: Dysmetabolic profile has been associated with native aortic valve stenosis. However, there are limited data on the effects of an atherogenic milieu and its potential implications on the structural and hemodynamic deterioration of aortic bioprosthetic valves. OBJECTIVES: This prospective longitudinal study sought to determine the predictors and impact on outcomes of hemodynamic valve deterioration (HVD) of surgically implanted aortic bioprostheses. METHODS: A total of 137 patients with an aortic bioprosthesis implanted for a median time of 6.7 (interquartile range: 5.1 to 9.1) years prospectively underwent a first (baseline) assessment with complete Doppler echocardiography, quantitation of bioprosthesis leaflet calcification by multidetector computed tomography (CT), and a fasting blood sample to assess cardiometabolic risk profile. All patients underwent a second (follow-up) Doppler echocardiography examination at 3 (interquartile range: 2.9 to 3.3) years post-baseline visit. HVD was defined by an annualized change in mean transprosthetic gradient ≥3 mm Hg/year and/or worsening or transprosthetic regurgitation by ≥1/3 class. The primary endpoint was a nonhierarchical composite of death from any cause or aortic reintervention procedure (redo surgical valve replacement or transcatheter valve-in-valve implantation) for bioprosthesis failure. RESULTS: Thirty-four patients (25.6%) had leaflet calcification on baseline CT, and 18 patients (13.1%) developed an HVD between baseline and follow-up echocardiography. Fifty-two patients (38.0%) met the primary endpoint during subsequent follow-up after the second echocardiographic examination. Leaflet calcification (hazard ratio [HR]: 2.58; 95% confidence interval [CI]: 1.35 to 4.82; p = 0.005) and HVD (HR: 5.12; 95% CI: 2.57 to 9.71; p < 0.001) were independent predictors of the primary endpoint. Leaflet calcification, insulin resistance (homeostatic model assessment index ≥2.7), lipoprotein-associated phospholipase A2 activity (Lp-PLA2 per 0.1 nmol/min/ml increase), and high level of proprotein convertase subtilisin/kexin 9 (PCSK9) (≥305 ng/ml) were associated with the development of HVD after adjusting for age, sex, and time interval since aortic valve replacement. CONCLUSIONS: HVD identified by Doppler echocardiography is independently associated with a marked increase in the risk of valve reintervention or mortality in patients with a surgical aortic bioprosthesis. A dysmetabolic profile characterized by elevated plasma Lp-PLA2, PCSK9, and homeostatic model assessment index was associated with increased risk of HVD. The presence of leaflet calcification as detected by CT was a strong predictor of HVD, providing incremental risk-predictive capacity.
BACKGROUND: Dysmetabolic profile has been associated with native aortic valve stenosis. However, there are limited data on the effects of an atherogenic milieu and its potential implications on the structural and hemodynamic deterioration of aortic bioprosthetic valves. OBJECTIVES: This prospective longitudinal study sought to determine the predictors and impact on outcomes of hemodynamic valve deterioration (HVD) of surgically implanted aortic bioprostheses. METHODS: A total of 137 patients with an aortic bioprosthesis implanted for a median time of 6.7 (interquartile range: 5.1 to 9.1) years prospectively underwent a first (baseline) assessment with complete Doppler echocardiography, quantitation of bioprosthesis leaflet calcification by multidetector computed tomography (CT), and a fasting blood sample to assess cardiometabolic risk profile. All patients underwent a second (follow-up) Doppler echocardiography examination at 3 (interquartile range: 2.9 to 3.3) years post-baseline visit. HVD was defined by an annualized change in mean transprosthetic gradient ≥3 mm Hg/year and/or worsening or transprosthetic regurgitation by ≥1/3 class. The primary endpoint was a nonhierarchical composite of death from any cause or aortic reintervention procedure (redo surgical valve replacement or transcatheter valve-in-valve implantation) for bioprosthesis failure. RESULTS: Thirty-four patients (25.6%) had leaflet calcification on baseline CT, and 18 patients (13.1%) developed an HVD between baseline and follow-up echocardiography. Fifty-two patients (38.0%) met the primary endpoint during subsequent follow-up after the second echocardiographic examination. Leaflet calcification (hazard ratio [HR]: 2.58; 95% confidence interval [CI]: 1.35 to 4.82; p = 0.005) and HVD (HR: 5.12; 95% CI: 2.57 to 9.71; p < 0.001) were independent predictors of the primary endpoint. Leaflet calcification, insulin resistance (homeostatic model assessment index ≥2.7), lipoprotein-associated phospholipase A2 activity (Lp-PLA2 per 0.1 nmol/min/ml increase), and high level of proprotein convertase subtilisin/kexin 9 (PCSK9) (≥305 ng/ml) were associated with the development of HVD after adjusting for age, sex, and time interval since aortic valve replacement. CONCLUSIONS: HVD identified by Doppler echocardiography is independently associated with a marked increase in the risk of valve reintervention or mortality in patients with a surgical aortic bioprosthesis. A dysmetabolic profile characterized by elevated plasma Lp-PLA2, PCSK9, and homeostatic model assessment index was associated with increased risk of HVD. The presence of leaflet calcification as detected by CT was a strong predictor of HVD, providing incremental risk-predictive capacity.
Authors: Jacek Kwiecinski; Evangelos Tzolos; Timothy R G Cartlidge; Stephanie L Sellers; Daniel S Berman; Marc R Dweck; Alexander Fletcher; Mhairi K Doris; Rong Bing; Jason M Tarkin; Michael A Seidman; Gaurav S Gulsin; Nicholas L Cruden; Anna K Barton; Neal G Uren; Michelle C Williams; Edwin J R van Beek; Jonathon Leipsic; Damini Dey; Raj R Makkar; Piotr J Slomka; James H F Rudd; David E Newby Journal: Circulation Date: 2021-08-29 Impact factor: 39.918
Authors: David Šuran; Helena Blažun Vošner; Jernej Završnik; Peter Kokol; Andreja Sinkovič; Vojko Kanič; Marko Kokol; Franjo Naji; Tadej Završnik Journal: Front Public Health Date: 2022-07-05
Authors: Denise Traxler; Pavla Krotka; Maria Laggner; Michael Mildner; Alexandra Graf; Berthold Reichardt; Ralph Wendt; Johann Auer; Bernhard Moser; Julia Mascherbauer; Hendrik Jan Ankersmit Journal: Eur J Clin Invest Date: 2021-12-30 Impact factor: 5.722
Authors: Nicolas Perrot; Vincenza Valerio; Donato Moschetta; S Matthijs Boekholdt; Christian Dina; Hao Yu Chen; Erik Abner; Andreas Martinsson; Hasanga D Manikpurage; Sidwell Rigade; Romain Capoulade; Elvira Mass; Marie-Annick Clavel; Thierry Le Tourneau; David Messika-Zeitoun; Nicholas J Wareham; James C Engert; Gianluca Polvani; Philippe Pibarot; Tõnu Esko; J Gustav Smith; Patrick Mathieu; George Thanassoulis; Jean-Jacques Schott; Yohan Bossé; Marina Camera; Sébastien Thériault; Paolo Poggio; Benoit J Arsenault Journal: JACC Basic Transl Sci Date: 2020-07-01
Authors: Alexander E Kostyunin; Arseniy E Yuzhalin; Maria A Rezvova; Evgeniy A Ovcharenko; Tatiana V Glushkova; Anton G Kutikhin Journal: J Am Heart Assoc Date: 2020-09-21 Impact factor: 5.501